Grants for Nonprofits - Science and Technology

The North Central Region SARE (NCR-SARE) Research and Education (R&E) Grant Program is a competitive funding opportunity offering $100,000 to $500,000 for up to 3 years to researchers, educators, and organizations exploring sustainable agriculture, with the aim of improving economic viability, environmental quality, and quality of life in the North Central Region's agricultural sector.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat or service-related orthopaedic injuries that significantly impact unit readiness and return-to-duty/work rates. Applicants are encouraged to address how the proposed research will support patient care closer to the point of injury and/or allow patients to more quickly return to duty/work. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.The FY24 PRORP CTA differs from the FY24 PRORP Clinical Translational Research Award (CTRA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support a clinical trial and may not be used for animal or preclinical studies. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.All applications submitted to this program announcement, regardless of the selected Focus Area, are eligible for Research Level 1.Collaborative Care Option (Research Level 2): Applications submitted to the FY24 PRORP CTA, with Focus Area Translation of Early Findings Soft Tissue Trauma, are eligible for a Collaborative Care Option (Research Level 2); refer to Section II.D.5, Funding Restrictions. The Collaborative Care Option provides additional support to encourage collaborative interdisciplinary research among physical therapists, occupational therapists, prosthetists, surgeons, and other orthopaedic care providers. The proposed research should include both surgical and rehabilitation strategies that create a cohesive project. Surgical strategies are reconstruction and repair and/or application of biologics, pharmaceuticals, and devices for the purpose of restoration of native architecture, composition, and function of traumatically injured tissues. Rehabilitative strategies are those that restore function following injury or illness, with the goal of optimal health and independence. Projects should integrate principles and approaches from surgical and rehabilitative strategies, beyond what each approach would provide by itself, with the goal of optimizing form, function, and independence for those who have sustained traumatic orthopaedic injuries. The rehabilitation strategy and the standard of care must be specified. Projects that follow patients across the continuum of care are highly encouraged. To encourage meaningful and productive multidisciplinary collaborations, projects submitted for this option must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care. A Letter of Collaboration is required from each specialist (i.e., rehabilitation expert and surgeon) who is serving as Key Personnel, excluding the Principal Investigator (PI), on the application. A clinician is defined as an individual who is credentialed (possesses the necessary degrees, licenses, and other certifications) and practicing as a care provider in a relevant capacity.If the proposed research includes a clinical trial of an investigational product to be conducted at international sites, an application to the relevant national Regulatory Agency of each host country must be submitted within 6 months of the award date.The government reserves the right to withdraw funding if an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application and/or international regulatory application is necessary but has not been submitted within 6 months of the award date.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Key aspects of the PRORP CTA mechanism: Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 6 months after the award date, or 12 months after the award date for studies regulated by the Regulatory Agency. Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of U.S. Food and Drug Administration (FDA) processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in 21 CFR 312, Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.Womens Health Research: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.Use of DOD or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international Regulatory Agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTA should not exceed $2.5M (Research Level 1) or $3.25M (Research Level 2). Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.25M to fund approximately four Research Level 1 and one Research Level 2 CTA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports nonprofit organizations in Manhattan and Riley County, Kansas, to create accessible and lasting public arts projects that enrich community life.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Levels 1 and 2. Funding Levels 3 and 4 are available under other program announcements (HT942524BCRPBTA3 and HT942524BCRPBTA4, respectively). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcement before submitting the pre-application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement: Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome. Funding Level 2: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within thebreast cancer landscape. Funding Level 2: Population Science and Prevention Studies: Population Science and Prevention Studies should involve investigations into why certain human patient populations differ in cancer risk or clinical prognosis. The studies should focus on the analysis of human data and biospecimens. Research should be already supported by substantial preliminary or published data and strongly validate clinical translation in a well-defined context within the breast cancer landscape. With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Levels 1 and 2 applications unless they are clearly unique, meaningful partnerships addressing distinct research questions. Applications in which a mentor and their current postdoctoral fellow or junior investigator are named as Initiating and Partnering PIs do not meet the intent of the Partnering PI Option. Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most, or all of the experiments and analyses, do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Research involving human subjects and research involving human anatomical substances and data is permitted; however, clinical trials are not allowed under this funding opportunity.Applications seeking support for a clinical trial may be submitted to the FY24 BCRP Breakthrough Award Level 3 and Level 4 program announcements (HT942524BCRPBTA3 and HT942524BCRPBTA4, respectively).A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Funding Level 1 should not exceed $450,000 for applications with a single PI or $750,000 if applying under the Partnering PI Option.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Level 2 should not exceed $1.0M for applications with a single PI or $1.5M if applying under the Partnering PI Option.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Funding Level 2, Population Science and Prevention Studies, should not exceed $1.5M for applications with a single PI or $2.0M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $20.9M to fund approximately 14 Breakthrough Award Levels 1 and 2 applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Emporia Community Foundation in Butler County, Kansas is offering a grant through the Flint Hills Community Fund for community and rural development, museums/historic preservation, and agriculture and conservation projects, prioritizing those with high volunteer involvement and organizations looking to expand, with applications due by 09/30/2024.

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project. These data may be unpublished or from the published literature.

Grant Name: CCEF Rapid Grants Location: Georgia Description: The Cherokee County Educational Foundation (CCEF) is offering rapid grants to support growth and innovation in the Cherokee County School District. These grants, with funding of up to $500, are available to all faculty members for activities such as inviting authors to speak, organizing in-school field trips, and conducting science lab projects. The aim is to provide teachers and students with the necessary tools to make learning exciting. For more details, visit the Rapid Grants webpage.

The Rowan Arts Council (RAC) Grassroots Arts grants are provided annually to non-profit organizations operating arts programs within Rowan County, North Carolina. This program is funded through the NC General Assembly via the NC Arts Council Grassroots Arts Program, with the RAC acting as the Designated County Partner. The primary mission of these grants aligns with enhancing and strengthening the cultural community and broadening artistic services available to Rowan County citizens. The program focuses on fostering a vibrant arts scene and making arts accessible to a wider audience, contributing to the cultural enrichment of the region. The grants target a diverse range of beneficiaries, including qualified arts organizations such as theaters, symphonies, galleries, art guilds, choral societies, dance companies, folk arts societies, writer’s groups, and arts festivals. Additionally, the program supports arts learning and arts in education initiatives for students and adults, as well as community organizations providing quality art experiences. The expected outcomes include a more robust cultural landscape, increased participation in arts programs, and expanded artistic services. Measurable results could include the number of organizations supported, the number of individuals reached through various programs, and the diversity of artistic offerings. The program prioritizes funding in three key areas. The first priority is to offer program or operating support to qualified arts organizations that do not receive funding directly from the N.C. Arts Council’s State Arts Resources. The second priority is to support arts learning and arts in education programs, such as artist residencies in schools, after-school camps, or adult arts classes, provided these activities are not part of a school's internal arts curriculum or for the purchase of art supplies or student competitions. The third priority is to support other community organizations that provide quality art experiences for the greater community, ensuring these programs are conducted by qualified artists. Grassroots Arts Program funds can be utilized across various artistic disciplines, including visual arts, crafts, dance, drama, film and video, folk arts, literature, music, photography, architecture, and the visual environment. Typical uses of funds encompass program expenses like artists’ fees, travel, space rental, advertising, and supplies, as well as program administration and operating expenses such. While salaries and equipment are allowable, their use is generally limited. The program strategically aims to build a strong, self-sustaining arts community in Rowan County by empowering local organizations and artists, which aligns with a theory of change that increased local investment in the arts leads to broader community engagement and cultural development.

This funding opportunity provides financial support for researchers at domestic institutions to study atmospheric processes using data from the Department of Energy's ARM facility, with a focus on improving climate models and understanding critical environmental factors.

This funding opportunity supports researchers and educational institutions in developing engineered microbial communities to advance scientific understanding and practical solutions for climate change, sustainability, and biotechnology.

This funding opportunity supports research and development projects aimed at advancing air dominance technologies, targeting higher education institutions, non-profits, for-profits, and small businesses involved in innovative defense solutions.

Texas Mutual is offering a grant program designed to create generational impact and build a stronger, safer Texas for working families. This initiative aligns directly with their mission to support the well-being of the state's workforce and their dependents. The grant's duration is one year, with funding requests encouraged between $25,000 and $100,000, though the overall size of the grant can range from $10,000 to $100,000. The primary beneficiaries of this funding cycle are Texas workers and their families, with a focus on improving health and wellness, and expanding access to quality early childhood education. The grant also targets clients who require holistic wraparound support in addition to case management to overcome multiple barriers and seize opportunities. The overarching impact goals are to enhance health outcomes, improve educational access for young children, and provide comprehensive support systems for families in need. The program's priorities and focuses for this grant cycle include organizations dedicated to improving the health and wellness of Texas workers and their families by ensuring access to quality care and health education. Another key area is strengthening the early childhood education system, specifically by equipping child care providers with the necessary resources to deliver affordable, quality education. Finally, the grant seeks to support nonprofits that provide or coordinate integrated care, addressing various barriers through holistic wraparound support and case management. Texas Mutual's strategic priorities are centered on long-term societal improvement through targeted investments. Their theory of change appears to be that by investing in health, education, and comprehensive family support, they can create a ripple effect that leads to a stronger, safer, and more prosperous Texas for working families across generations. This involves ensuring that organizations are actively delivering technical assistance and services within Texas communities. Expected outcomes include increased access to quality healthcare and health education for Texas workers, an enhanced early childhood education system with more accessible and affordable options, and improved stability and opportunity for families through integrated support services. While specific measurable results are not detailed, the focus on "generational impact" suggests long-term, sustainable improvements in the well-being and socio-economic conditions of Texas working families as a result of these initiatives.

This grant provides funding for researchers to explore the impacts of environmental changes on biodiversity and its functions, encouraging innovative studies that connect ecological and evolutionary perspectives on a global scale.

The Division of Earth Sciences (EAR) invites the submission of proposals for collaborative, interdisciplinary studies of the Earth's interior within the framework of the community-based initiative known as Cooperative Studies of the Earth's Deep Interior (CSEDI). Funding will support basic research on the character and dynamics of the Earth's mantle and core, their influence on the evolution of the Earth as a whole, and on processes operating within the deep interior that affect or are expressed on the Earth's surface. Projects may employ any combination of field, laboratory, and computational studies with observational, theoretical, or experimental approaches. Support is available for research and research infrastructure through grants and cooperative agreements awarded in response to investigator-initiated proposals from U.S. universities and other eligible institutions. Interdisciplinary projects are required.

This funding opportunity is designed to support research initiatives that enhance the understanding and management of Atlantic bluefin tuna populations, particularly through collaboration with international partners involved in their conservation.

ADVS is the state agency responsible for the 600,000 service members, Veterans, and family members that call Arizona home. To that end, ADVS collaborates with public and private stakeholders to implement initiatives that positively influence the lives of Arizona’s military, Veteran, and family population.  ADVS is supporting the ongoing statewide collective impact efforts and implementation of three (3) Veteran initiatives focused on ending Veteran homelessness, assisting with Veteran employment barriers, and providing a pathway to providing Veterans with a higher level of care. ADVS is committed to the implementation of these Veteran Initiatives, which includes providing programs and services focusing on a community-based Veteran Homeless Action Plan to meet the needs of Veterans and their families through outreach, housing services, employment barriers, connection to VA community resources, and facilitating Veterans transition into a higher level of care.   AZ Action Plan to End Homeless Veterans Introduction: ADVS provides critical, statewide coordination and technical assistance to services and organizations serving Veterans. This includes activities such as the Arizona Veteran StandDowns, outreach events that support homeless and at-risk military Veterans in Coconino, Graham, Greenlee, La Paz, Maricopa, Mohave, Pima, Pinal, Santa Cruz, Yavapai and Yuma Counties. This solicitation looks to expand the reach and capacity of Arizona Department of Veterans' Services to serve Arizona Veterans. AZHC is a statewide organization and have served Veterans and their families for many years. Project Objectives: Host the Maricopa County StandDown, the largest serving StandDown in the nation. The event serves over 2,000 homeless and at-risk Veterans each year.  Provide leadership, coordination, technical assistance, and bridge funding  throughout the year. Foster collaborations with new partners to serve  Veterans in need. Seek to prioritize the Maricopa County StandDown efforts towards  Veterans who  are street-living homeless without jeopardizing the accuracy of the      data of  Veterans' housing status. Provide financial assistance to Veterans in need in the form of bridge housing or mitigation assistance throughout the year in Maricopa County. Provide financial and technical assistance to the 11 StandDowns throughout the state. Collect accurate information of how many Veterans are experiencing homelessness or housing instability. Outreach to other communities currently hosting or considering hosting   StandDown or at-risk Veteran resource events. Develop relationships and provide assistance to foster future collaborations under the Arizona Veteran StandDown Alliance. Provide After-Action reports for each event, shared with the Arizona Department  of Veterans' Services, and accessible to the community on our website. Veteran Toolkit  Introduction: ADVS with the help of the Arizona Coalition for Military Families has launched the  roadmap to Veterans Employment. This strategy outlines various initiatives to assist Veterans with obtaining employment. As often is the case, the veteran has been unemployed or under employed, and may not have the funds to buy the required protective  equipment, tools, or supplies needed for work. Project Objectives: The purpose of this section is to outline the scope of work of the grantee and   deliverables due to ADVS. Grantee will receive referrals from employment service providers (DVOP, LVER, Community workforce development services etc.) and provide identified          veteran recipients with an intervention that enables gainful employment. Grantee will ensure that the intervention occurs within 48 hours of a regular workweek. All monetary interventions must be receipted and submitted monthly for ADVS reporting. Financial assistance may not be given directly to the veteran; equipment, tools, and supplies must be acquired for them. Veteran must sign and acknowledge they have received assistance, to include any items purchased for obtaining gainful employment. Hero’s Pathway to Hope The Arizona Department of Veterans' Services (ADVS) is the State agency responsible for the 600,000-service member, veterans and family members that call Arizona home. The ADVS mission is to be the catalyst in response to the evolving needs if Arizona’s veterans and their families. To that end, ADVS partners with public and private stakeholders and community partners to implement initiative that positively impact the lives of Arizona's military, veteran and family population. The State of Arizona is seeing increasingly high numbers of homeless veterans who cannot be housed due to a combination of financial difficulties and high acuity needs. Project Objectives: Lead a multi-agency team of public and private partners to ensure programmatic goals are met tee will be responsible for facilitating communication through email and virtual  meetings throughout the duration of the Pilot. Grantee will give a complete overview of Pilot during the briefing process where the Veteran will sign and Inter-Agency ROI, Acknowledgment of Program      Guidelines and data collection. During briefing process Grantee will provide clear and concise information that the Veteran in entering into a voluntary Pilot Program, which includes the possibility of denial of applications and termination of funding within the three (3) month bridge of placement. Collect pilot data to inform program needs beyond the pilot. Provide Promise to Pay letter to be sent to Placement Facility, Veteran and assigned VA Social Worker. Notice of Funds ending letter will be sent to Facility and Partnering Agencies; notifying Facility of thirty (30) day end of funds date. Grantee will provide a report of monthly expenses for each Veteran participating in the Pilot and a report of data findings within ninety (90) days of conclusion of the  Pilot. Financial Notes: The State of Arizona is seeing increasingly high numbers of homeless veterans who cannot be housed due to a combination of financial difficulties and high acuity needs. Provide financial assistance to Veterans in need in the form of bridge housing or mitigation assistance throughout the year in Maricopa County. Provide financial and technical assistance to the 11 StandDowns throughout the state. Collect accurate information on how many Veterans are experiencing homelessness or housing instability. Advocate for additional financial resources at the federal, state, and local levels to support housing and homelessness services, including advocating for the restoration of the state housing trust fund. Financial assistance may not be given directly to the veteran; equipment, tools, and supplies must be acquired for them.

The Community Foundation of Northeast Alabama is offering the Summit Grant Program, which is designed to strengthen not-for-profit organizations in its service area. This program aligns with the Foundation's mission by encouraging short-term (12-month) projects that advance community leadership development, training, and organizational technology. The Foundation seeks to support organizations that contribute to the overall well-being and progress of the communities within its nine-county service area. The target beneficiaries of the Summit Grant are 501(c)(3) qualified public charities that have been physically located and operating for at least one year in Calhoun, Cherokee, Clay, Cleburne, DeKalb, Etowah, Randolph, St. Clair, or Talladega counties in Alabama. The program aims to impact these organizations by fostering stronger community leadership and improving their technological capabilities. The grant prioritizes two main focus areas: Community Leadership Development and Training, and Organizational Technology Advancement. Within leadership development, the program seeks to support local city councils, school boards, not-for-profit senior leadership staff, not-for-profit boards, and county commissions. For technology advancement, the focus is on improving gift and donor tracking systems, enhancing remote work capabilities, updating current technology, improving financial tracking systems, and strengthening cybersecurity. The expected outcomes include strengthened not-for-profit organizations with improved leadership and enhanced technological infrastructure. Measurable results would involve the successful implementation of 12-month projects, leading to advancements in the specified focus areas. For example, improved donor tracking systems would lead to better fundraising, and leadership training would result in more effective community governance. The Foundation's strategic priorities and theory of change are centered on the belief that by investing in the capacity of local not-for-profit organizations, they can foster stronger, more resilient communities. By supporting both leadership development and technological advancement, the Summit Grant aims to create a ripple effect, empowering these organizations to more effectively serve their communities and achieve their respective missions. With $30,000 in total funding available and individual grants ranging from $1,000 to $10,000, the program provides vital resources to achieve these strategic objectives over a one-year duration.

The DOD Pancreatic Cancer, Focused Pilot Award is a grant that supports innovative research projects aimed at improving the quality of life for pancreatic cancer patients, with a focus on areas such as healthcare access, mental health, psycho-social issues, nutrition, education, and symptom management.

This funding opportunity supports artists and arts organizations in Akron, Detroit, and Miami-Dade County to enhance their digital practices and community engagement through technology.